

Celiac Disease and Obesity: Is Bariatric Surgery an Option?

Manon Lojou, Nicolas Sahakian, Anne Dutour, Geoffroy Vanbiervliet, Thierry Bege, Benedicte Gaborit

► **To cite this version:**

Manon Lojou, Nicolas Sahakian, Anne Dutour, Geoffroy Vanbiervliet, Thierry Bege, et al.. Celiac Disease and Obesity: Is Bariatric Surgery an Option?. Obesity Surgery, Springer Verlag, 2020, 30 (7), pp.2791-2799. 10.1007/s11695-020-04607-z . hal-03158851

HAL Id: hal-03158851

<https://hal.inrae.fr/hal-03158851>

Submitted on 16 Mar 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

CELIAC DISEASE AND OBESITY: IS BARIATRIC SURGERY AN OPTION?

**Lojou M¹, M.D., Sahakian N¹, M.D., Dutour A^{1,2}, M.D., Ph.D, Vanbiervliet G³ M.D.,
Ph.D, Bege T^{4,5} M.D., Ph.D, Gaborit B^{1,2} M.D., Ph.D.**

5 ¹ Department of Endocrinology, Metabolic disease and Nutrition,
Assistance Publique–Hôpitaux de Marseille, France

² Aix-Marseille University, INSERM, INRAE, C2VN, Marseille, France

³ Digestive Medicine, L'Archet 2 University Hospital–Nice, France

10 ⁴ Department of Digestive Surgery, Hôpital Nord, Aix-Marseille University, Chemin des
Bourrely, 13915 Marseille Cedex 20, France

⁵ Aix-Marseille University, IFSTTAR, LBA, Marseille, France

Corresponding author:

15 **Bénédicte Gaborit: Department of Endocrinology, Metabolic Disease and Nutrition,
Pole ENDO, Hôpital Nord, Chemin des Bourrely, 13915 Marseille Cedex 20, France.**

Phone: +33 49196 8823; Fax: +33 49196 8878; Email: Benedicte.GABORIT@ap-hm.fr

Abstract

20 Celiac disease (CD) is an immune-mediated enteropathy associated with malabsorptive
syndrome and fat-soluble vitamin deficiencies. CD affects one percent of individuals but is
largely underdiagnosed, as its multifaceted clinical presentations create challenging diagnostic
scenarios. With the rise of the obesity epidemic, doctors are increasingly seeing CD patients
with overweight or obesity, which raises the question of bariatric surgery. However, few
25 studies so far have investigated bariatric surgery in this patient population. Here we provide a
comprehensive review of the literature on CD, its nutritional consequences and complications,
and we discuss the possible impact of bariatric surgery on weight loss, nutritional
deficiencies, response to gluten-free diet, and long-term post-operative complications. We
also review the effect of bariatric surgery on the incidence of CD.

30

Keywords: Celiac disease, bariatric surgery, obesity, gluten-free diet, Roux-en-Y bypass,
sleeve gastrectomy

Introduction

35 Celiac disease (CD) is an autoimmune disorder that can occur in genetically predisposed
people where the ingestion of gluten leads to damage in small intestine[1]. It is characterized
by villous atrophy inducing a malabsorption syndrome [2]. CD was classically defined in the
child as a chronic enteropathy with villous atrophy secondary to an inappropriate immune
response of the intestinal mucosa to the gliadin in wheat, barley and rye. The disorder often
40 presents with diarrhea, malabsorption of one or more nutrients, and resultant weight loss, and
it involves a mucosal inflammatory response that extends from the duodenum into the more
distal small intestine for variable distances.

CD is heavily underdiagnosed, due to its many variable clinical symptoms and multi-organ
manifestations (Figure 1). Diagnosis of CD is based on the presence of predisposing genetic
45 factor human leukocyte antigen (HLA) DQ2/8 haplotypes, with positive small intestine
biopsy and serological antibodies upon a gluten-containing diet[3]. Histological confirmation
of CD diagnosis is based on demonstrated small bowel mucosal villous atrophy,
intraepithelial lymphocytosis and crypt hyperplasia in biopsy samples obtained by
gastroscopy [4,5].

50 The spectrum of CD may present in different forms. The classical form may be diagnosed at
any age of life and is often characterized by crypt hyperplasia and villous atrophy along with
features of malabsorption [1,6]. Diarrhea, steatorrhea, weight loss or growth failure is
required. The atypical form is characterized by positive celiac serology, limited abnormalities
of the small intestinal mucosa or no intestinal symptoms, but associated extraintestinal
55 conditions such as osteoporosis, peripheral neuropathy, anemia and infertility. The latent form
is defined by presence of predisposing gene HLADQ2 and/or HLA-DQ8, normal intestinal
mucosa and, possible positive serology [3]. This changing face of CD (more latent than

classical form) is accompanied by a change in diagnostic strategies but also in the whole definition of the disease itself [7].

60 Historically, patients with CD were more frequently underweight, but nowadays CD patients are increasingly overweight or obese [8,9]. Some who are severely obese are candidates for bariatric surgical management. Bariatric surgery is generally safe, feasible and effective in patients with autoimmune disorders [10,11]. However, in certain types of surgery, co-existing malabsorptive processes may further increase the risk of post-operative complications or
65 nutritional deficiencies. This review provides a thorough appraisal of CD in the context of obesity, its nutritional consequences and complications, and opens discussion on the possible impact of bariatric surgery on weight loss, nutritional deficiencies, response to gluten-free diet, and long-term post-operative complications.

Epidemiology of celiac disease

70 The prevalence of CD has increased significantly over the past fifty years, partly due to better diagnostic tools and screening of individuals at high risk for the disorder [2]. In Western countries, the prevalence of CD is between 0.6 and 1% in the general population, but a much more prevalent 3–6% in type 1 diabetics, 5–10% in the first-degree relatives of a CD patient, from 1 to 3% in osteoporotic patients and from 3% to 15% in patients with iron-deficiency
75 anemia [12]. The prevalence of CD varies according to ethnic origin. It is high in Caucasians compared to Blacks and Hispanics, which appears to correlate with the frequency of patients with a predisposing HLA gene. The prevalence of CD in European countries was found to be 1% (among 29,212 patients from Finland, Germany, Italy and the UK). Incidences close to those of Europe or the United States were noted in North Africa, the Middle East and India.
80 On the other hand, CD is almost unseen in Southeast Asia and Black Africa.

Note that 30% of Caucasian populations carry HLA-DQ2, and most will eat wheat, while only 1 in 100 will develop the disease. The remaining susceptibility is thought to be due to a combination of genetic and environmental factors [3]. Overall, the HLA-DQ2 haplotype confers the highest genetic risk for developing CD. There is also a general consensus that female gender and a family history of CD are also risk factors. In a recent publication, higher gluten intake during the first 5 years of life was associated with increased risk of CD autoimmunity and CD among genetically predisposed children carrying HLA antigen genotypes associated with type 1 diabetes and CD [13].

The incidence of CD has increased significantly over the last 30 years, from 2–3 to 9 or 13 new cases per 100,000 inhabitants per year [14–16]. This increase in incidence over time probably reflects more recognition of atypical and latent forms through serological testing. Differences in the prevalence of predisposition genes and food diversification practices (gluten introduced earlier or later in life) could also explain the geographical variations and—over time—incidence of the disease. However, the majority of patients with CD remain undetected worldwide, and several reports have suggested that upper gastrointestinal surgeries may unmask undiagnosed CD [2].

Nutritional consequences of celiac disease

There are two types of intestinal mucosal damage: first a reduction in the number of mature absorptive cells, and second a dysfunction of the remaining cells characterized by villous atrophy (flattening of the mucosa and reduction of the absorptive surface).

Reduced levels of iron, folate, vitamin B12, vitamin D, zinc and magnesium are common in untreated CD patients, probably due to a loss of brush border proteins and enzymes needed for the absorption of these nutrients. In a majority of patients, removing gluten from the diet

105 leads to histological recovery and normalization of iron, vitamin and mineral levels. Iron-
deficiency anemia is the most common extra-intestinal sign of CD and usually resolves with
adherence to a gluten-free diet. However, deficiencies of both folate and vitamin B12 may
persist in some patients on a gluten-free diet, thus requiring vitamin supplementation to
improve health status. Similarly, bone mineral density does not always normalize after
110 excluding gluten from the diet, and in these cases vitamin D and calcium supplementation is
recommended. Furthermore, resolution of mucosal inflammation may not be enough to
abrogate magnesium deficiency. Since gluten-free cereal products have a lower magnesium
content than their gluten-containing counterparts, a magnesium-enriched diet should be
encouraged in CD patients [17]. **Table 1** summarizes the nutritional deficiencies frequently
115 reported with a gluten-free diet (GFD) [18–21].

In a study of 80 patients assessing the nutritional and vitamin/mineral status of current ‘early
diagnosed’ but untreated adult CD patients in the Netherlands, Wierdsma *et al.*[22] showed
that compared to healthy individuals, CD patients were most frequently deficient in folic acid
(20%, 16/80), followed by vitamin B12 (19%, 15/79), vitamin B6 (14.5%, 9/62), vitamin A
120 (7.5%, 4/53) and vitamin (25-hydroxy) D (4.5%, 1/21). Approximately 67% (26/39) of the
patients had zinc deficiency, 32.4% (23/71) had anemia, 46.2% (18/39) had insufficient iron
stores evidenced by low ferritin, and 25% (8/40) had iron-deficiency anemia. CD patients had
lower vitamin A and folic acid than healthy controls. Overall, 17% were malnourished (>10%
undesired weight loss), 22% of the women were underweight (BMI<18.5), and 29% of all
125 patients were overweight (BMI>25). Vitamin deficiencies were barely seen in healthy
controls, with the exception of vitamin B deficiency [22].

In a study of 39 biopsy-proven CD patients, 16 (41%) patients were vitamin B12-deficient
(<220 ng/L) and 16 (41%) patients (11 women and five men) were anemic [18]. Only 5/16
(31%) of the vitamin B12-deficient patients were also folate-deficient. The Schilling test,

130 performed in 10 of the vitamin B12-deficient patients, showed five low and five normal results. Although only five patients received parenteral vitamin B12, the vitamin B12 levels had normalized in all patients at follow-up. Three vitamin B12-deficient patients had acral paresthesia at presentation that resolved after vitamin B12 replacement [18].

A well-led gluten-free diet will correct most vitamin and trace element deficits.

135 Deora *et al.*[23] evaluated the prevalence of micronutrient deficiencies in 140 CD patients under 17 years old and measured serum micronutrient levels and IgA-class anti-transglutaminase antibodies at diagnosis, 6 months and 18 months after starting a GFD. At diagnosis, serum vitamin D was the most commonly deficient vitamin in 70% of children. Serum ferritin was subnormal in 34.5% along with zinc in 18.6% of children, and remarkably,
140 only 12 (10.9%) children had iron-deficiency anemia. There was no correlation between micronutrient deficiencies at diagnosis and serum transglutaminase IgA antibody or degree of villous atrophy. Reassuringly, the measured serum micronutrient levels had mostly normalized at 6 months after starting GFD, except for vitamin D which improved but remained subnormal [23].

145 Nevertheless, the GFD remains a difficult diet to follow, with compliance problems, that may lead to the exclusion of certain foods and therefore other nutritional deficiencies. CD is a life-long disorder, and effective treatment with a strict GFD is difficult and usually time-consuming for the patient.

Severe complications of celiac disease

150 The two main serious and feared complications of CD are intestinal lymphoma and small bowel adenocarcinoma [1,2].

Lymphoma complications of CD are rare, with an incidence of less than 3 per 100,000 inhabitants per year, but serious. One identified lymphoma complication is clonal refractory

sprue, known as type II (SR II). SR II is an intra-epithelial lymphoma with a low degree of malignancy that is associated with CD and characterized by an expansion of small intraepithelial lymphocytes of abnormal phenotype. Its course can evolve into high-malignancy T-lymphoma in 30 to 50% of cases at 5 years, and its prognosis is bleak, with less than 45% of patients alive 5 years after diagnosis [24,25]. Diagnosis is difficult and requires specific immunohistochemical, phenotyping and molecular studies. Emerging from the small intestine, the abnormal intraepithelial lymphocytes can spread through the entire digestive tract (distal small intestine, stomach, and colon), circulate in the blood, and invade the bone marrow and various epithelia such as the epitheliotropic skin and lungs. More recently, granular leukemias (like large granular lymphocytic leukemia) have been identified which, from the periphery, invade the intestine of CD patients, often leading to GFD resistance.

These high-malignancy T-lymphomas (enteropathy-associated T-lymphoma; EATL) are rare (incidence estimated between 0.22 and 1.9 per 100,000 inhabitants) but with a bleak outcome. EATL may be diagnosed through surgery revealing CD, but when CD is already diagnosed, it is important to screen for lymphoma in case of resistance to GFD, whereas diagnosis after roux-en-Y gastric bypass (RYGB) can prove complex due to the excluded jejunum.

There is a reported increase in the risk of small bowel adenocarcinoma in patients with CD (odds ratio ranges between 4.3 to 60.0) that is usually detectable in the jejunum [26]. Indeed, in a study that evaluated the frequency of small-bowel malignancy in the UK and its relationship to the presence of CD, the authors found a diagnosis of CD in 13% of adenocarcinoma cases and in 39% of lymphomas, which highlights the fact that CD confers susceptibility to small bowel adenocarcinoma as well as lymphoma [27]. Unlike intestinal lymphoma, small bowel adenocarcinoma is not preceded by refractory CD and should be suspected in cases of sudden intestinal (sub)occlusion and/or anemia [1]. In their retrospective

study, Sharma *et al.* found no increase in intestinal lymphoma (p=0.99) nor an increase in
180 small intestine adenocarcinoma in CD patients given bariatric surgery [28].

Prevalence of obesity in celiac disease and effect of gluten-free diet on weight

The worldwide surge in number of obese individuals is also increasing the number of CD
patients who are overweight or obese. CD had historically been diagnosed in underweight
185 patients, but the trends seem to be reversing. Overall, the majority of CD patients have a
normal BMI: the prevalence of underweight varies from 3% to 36%, and the prevalence of
overweight and obesity varies from 6% to 39% and from 3% to 13%, respectively [29–33].
Table 2 summarizes the prevalence of underweight, normal, overweight, and obese patients
among patients with CD. Comparative analysis versus general population data found that CD
190 women had a significantly lower BMI (21.9 vs 24.2 kg/m², p<0.0001) and fewer of them were
overweight (11% vs 21%, p<0.0001). More CD men had normal BMI (59.5% vs 34%, p
<0.0001), and fewer CD men were underweight (9.1% vs 26.7%, p<0.0001).

After 2.8 years of well-monitored GFD), 66% of underweight patients gained weight, while
54% of overweight patients and 47% of obese patients lost weight [31].

195 Many studies have found weight loss or stable weight in overweight or obese CD patients
under a well-conducted GFD [21,29,31,34]. Ukkola *et al.* [32] prospectively investigated
weight and disease-related issues in 698 newly-detected CD adults at diagnosis and after one
year on a GFD and compared the findings with figures for the general population. At
diagnosis, 4% of subjects were underweight, 57% normal, 28% overweight and 11% obese.
200 On a GFD, 69% of underweight patients gained weight and 18% of overweight and 42% of
obese lost weight; in the rest, BMI remained stable. Changes were similar in both symptom-
and screen-detected patients (23). Another team compared BMI at diagnosis and after 2 years
of treatment in patients with serological support for dietary compliance. Of GFD-compliant

patients, 81% had gained weight after 2 years, including 82% of initially overweight patients
205 [29]. In a study on more than 1000 patients over three years, 22% of GFD-compliant patients
gained weight, increasing their BMI by >2 pts [34]. Interestingly, when overweight or obese
children adhere to a GFD, they may actually improve or normalize their BMI, whereas
children of normal weight at the time of diagnosis are seemingly at risk for becoming
overweight when starting a GFD [35]. Table 3 recaps the effect of GFD on weight gain or
210 loss in adults, as reported to date.

Bariatric surgery and celiac disease

Bariatric surgery

Bariatric surgery (BS) is currently the most effective treatment for severe obesity. It has
developed exponentially in industrialized countries as it enables sustained weight loss,
215 improves comorbidities, and reduces cardiovascular and general mortality [36]. A recent large
database study found that sleeve gastrectomy (SG) accounted for 63% of procedures
performed, compared to 30% for Roux-en-Y gastric bypass (RYGB) and just 2% for
laparoscopic adjustable gastric banding (LAGB) [37]. However, it also has side effects
including nutritional deficiencies. Some of these deficiencies have demonstrated clinical
220 impact that is sometimes severe, such as neurological complications due to vitamin B12 or B1
deficiency, iron-deficiency anemia, and bone demineralization with risk of fracture due to
vitamin D and/or calcium deficiency.

There is growing consensus that BS leads to effective weight loss depending on type of
surgery performed. Weight loss can reach up to 40% of initial weight and increases with
225 malabsorptive procedures [38]. Percentage of excess weight loss varies from 47% for LAGB
to more than 60% with RYGB and 70% for biliopancreatic diversion or duodenal switch [39].

Patients who undergo BS are monitored by a multidisciplinary team that is especially attentive to early and late complications. Restrictive and/or malabsorptive interventions frequently cause nutritional deficiencies. The main origins of these deficiencies are a lack of digestive assimilation and a lack of dietary intake due to drastic reduction of caloric intake, and possible intolerance to certain foods (fibers, proteins). The main nutritional deficiencies following BS concern proteins and certain functional amino acids, iron, zinc, calcium, vitamin D and other liposoluble vitamins, folate, vitamin B12, and polyunsaturated fatty acids [40].

The American Society for Metabolic and Bariatric Surgery Integrated Health has updated its ‘nutritional guidelines for the surgical weight loss patient on micronutrients’ [38,41]. According to these guidelines, all types of surgery should systematically require thiamin, vitamin B12, folate, iron, calcium and vitamin D supplementation. Vitamin D deficiency is reported to occur in up to 100% of post-weight-loss surgery patients and folate deficiency in up to 65%. These guidelines also state that the prevalence of micronutrient deficiencies is increasing while patient monitoring at follow-up is decreasing, thus justifying a multidisciplinary approach and life-long follow-up. In the Practical Recommendations of the *Obesity Management Task Force of the European Association for the Study of Obesity* for post-bariatric surgery medical management, Busetto *et al.* [42] state that long-term mineral and multivitamin supplementation should be prescribed to every bariatric patient with medication doses adapted to the procedure. Periodic laboratory surveillance for nutritional deficiencies is recommended and supplementation should be individualized accordingly in patients with demonstrated micronutrient deficiencies [42]. While nutritional deficiencies are uncommon after purely gastric restrictive procedures not altering intestinal continuity, they become very common after surgical procedures inducing malabsorption. However, the

occurrence of nutritional deficits is also influenced by factors independent of surgical technique, such as regular and nutrient-dense food intake and adherence with post-operative
255 vitamin and mineral supplementation, which is far from guaranteed.

Celiac disease and bariatric surgery: reported outcomes and response to gluten-free diet

CD patients who fail to properly adhere to the GFD are exposed to a panel of vitamin deficiencies due to malabsorption syndrome. However, BS, and especially gastric bypass, also
260 increases the risk of deficiencies.

The literature suggests that BS is safe and feasible in patients with concomitant autoimmune, inflammatory and intestinal pathologies including systemic lupus erythematosus and inflammatory bowel disease [10,11]. However, the role of BS in obese CD patients is less well defined. Combining a malabsorptive state such as CD with a restrictive and/or additional
265 malabsorptive procedure may further increase the risk of post-operative complications or nutritional deficiencies.

Does the risk of malnutrition and complications secondary to vitamin deficiency compromise surgery? Should patients with CD be offered a purely restrictive bariatric procedure, as some have suggested?

270 The prevalence of CD in BS populations is relatively low, and few CD patients have undergone BS [28,43]. A study retrospectively reviewed 12,000 RYGB patients for either diagnosis (American Gastroenterological Association diagnostic criteria) or serum testing for CD [43]. Of these 12,000 patients, 342 had abnormal serology, only 3 patients (0.8%) were confirmed with CD diagnosed before the procedure, and only two followed a GFD. All were
275 female, with an average age of 33 years and a mean BMI of 44.07 kg/m². Interestingly, there was no significant difference in terms of weight loss or excess weight loss between CD and

non-CD bariatric patients. No patients were anemic nor had vitamin B12 or iron deficiencies at 12-month follow-up. However, two patients had vitamin D insufficiencies that responded to daily oral supplementation [43]. In a nationwide inpatient sample analysis between 2004
280 and 2014, Sharma *et al.* [28] identified 126 patients with CD that had undergone bariatric surgery. BS did not increase in mortality, but CD patients with obesity and prior BS were three times more likely to have vitamin D deficiency (IRR 3.5; 95%CI 1.6–7.7; p=0.002) or post-operative strictures (IRR 3.3; 95%CI 1.5–7.5; p=0.004)[28].

The effect of GFD on weight (in patients who benefited from BS) is a hugely controversial
285 topic. Some teams consider that it leads to weight gain in obese patients. An Italian team reported the case of a patient incidentally diagnosed with the silent form of CD 5 years after BS and who had changed his BMI from 35.2 to 38.4 after 12 months of GFD [44]. Their paper reports complete restoration of the intestinal mucosa within 12 months after starting GFD after BS (vertical banded gastroplasty) had been performed 5 years earlier [44].

290 On the other hand, cases where symptoms persist despite a well-followed GFD are defined as refractory sprue, which is a condition that leads to a risk of T-cell lymphoma (EATL) requiring endoscopic monitoring with duodenojejunal biopsies [25]. However, the realization of a gastric bypass would result in a more difficult endoscopic follow-up in these patients[45].

Moreover, it is difficult to differentiate the usual post-surgery digestive symptoms from the
295 persistence of symptoms related to a refractory disease like diarrhea.

As recommended by The *American College of Gastroenterology* [14] and the *European Society for the Study of Coeliac Disease* [2] recommend testing for CD in certain settings, especially before BS:

- Patients with symptoms, signs or laboratory evidence suggestive of malabsorption, such as chronic diarrhea with weight loss, steatorrhea, postprandial abdominal pain and bloating, or elevated serum aminotransferase levels when no other etiology is found
 - Patients with a first-degree relative who has a confirmed diagnosis of CD should be tested
 - Patients with type 1 diabetes mellitus should be screened regularly for CD, notably if there are any digestive symptoms, or signs or laboratory evidence suggestive of CD.
- Diarrhea is classically predominant in CD, but CD should be part of the differential diagnosis in cases of post-BS diarrhea so as not to misread a diagnosis.

Is there increased incidence of CD after bariatric surgery?

A recent study reported the first case of CD diagnosed in the follow-up of duodenal switch in a woman with severe diarrhea shortly after surgery. Final diagnosis was later made based on anti-transglutaminase antibodies. The authors suggest that CD should be ruled out in patients with typical or atypical symptoms after BS regardless of the latency of onset [46]. Another asymptomatic case reported after vertical banded gastroplasty was due to familial history [44]. The mechanism by which BS can unmask latent CD is still unknown. It is thought that transient bowel hyperpermeability following such procedures could lead to an antigenic overload, but altered nutrient absorption, motility, perioperative stress and hormone variations could also be implicated [2]. In susceptible patients, the heightened gluten challenge might then sufficiently stimulate the immune response to result in clinically apparent enteropathy [47].

320

Discussion

CD has traditionally been associated with malabsorption and insufficient body weight, but approximately 10% of CD patients are obese at diagnosis. They could, therefore, be potential

candidates for BS. With the current obesity epidemic and the increasing incidence of CD, this
325 situation is set to become more frequent in the near future, which raises issues concerning the
specific diagnosis, choice of bariatric procedure, and specific follow-up or complications. If a
malabsorptive procedure is decided, it may add to the complexity of diagnosing CD
complications. Furthermore, starting a GFD after BS could increase the risk of weight regain,
and so weight maintenance counselling should be an integral part of celiac dietary
330 education[34]. In addition, many processed gluten-free products have an increased glycemic
index with increased fat and lower proteins than gluten-containing meals, which raises the
challenge of achieving sufficient protein intake post-operatively [2,38].

Several teams have suggested a preoperative work-up of specific CD tests (anti-endomysial
and anti-transglutaminase antibodies and total IgA) before bariatric procedures. After
335 malabsorptive surgery, diagnosis of CD by duodenal biopsies during endoscopy is technically
more difficult in non-expert centers due to the excluded jejunum. In these cases, testing
exclusively by serology remains an option. Indeed, a negative CD-specific serology does not
completely rule out a diagnosis of CD, though it does make it much less likely.

The standard treatment of CD implementing a GFD is also successful in BS patients.
340 However, apart from a few case reports, little is known about onset, course, diagnosis and
management of CD following BS, particularly after sleeve gastrectomy and RYGB.

Should this type of surgery be indicated in patients with CD, including gastric bypass?

Should patients be screened pre-operatively in order to not miss the diagnosis and avoid the
increased risk of malabsorption deficiencies? Figure 1 recaps the clinical manifestations of
345 CD and the possible impact of BS on this protein-losing enteropathy.

This was argued in a recent study that reported 5 cases of patients diagnosed preoperatively.
Four of them were asymptomatic and one had chronic diarrhea and anemia. Three of them

underwent sleeve gastrectomy. The authors suggest that, given the increasing number of asymptomatic obese patients with CD, all patients should be screened preoperatively to adapt
350 the surgical strategy accordingly [48]. The authoritative international societies have not yet defined a specific surgical strategy according to CD screening results.

To sum up, the literature and the experience of leading groups converge to show that BS is possible and clearly an option in severe obese patients with CD as long as they are compliant
355 with the GFD and do not have preoperative vitamin deficiencies. However, multidisciplinary teams should carry out strengthened monitoring of vitamin status and protein intake and better frame the management of weight loss.

Based on the current state of the art, systematic preoperative screening for CD in bariatric patients cannot be recommended as it carries a cost and CD in BS is still rare. Nevertheless, it
360 should be part of the conversation with genetically-predisposed patients such as type 1 diabetics or patients with a family history of CD. More extensive studies in large populations with long-term follow-up are now needed to definitively answer these questions.

Conclusion

365 Currently, almost 10% of celiac patients are obese at diagnosis, and could therefore be potential candidates for BS depending on their BMI and comorbidities. In addition, in the case of latent CD, symptoms may be precipitated by gastrointestinal aggression such as BS. The issues of whether potential bariatric patients should systematically be screened for CD before surgery and whether the diagnosis of CD would influence the type of procedure merit
370 further evaluation.

Conflicts of interest

The authors declare that they have no conflicts of interest.

1. Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, et al. Celiac disease: a comprehensive current review. *BMC Med.* 2019;17:142.
2. Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. *United Eur Gastroenterol J.* 2019;7:583–613.
- 380 3. Gujral N, Freeman HJ, Thomson ABR. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. *World J Gastroenterol.* 2012;18:6036–59.
4. Husby S, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. *J Pediatr Gastroenterol Nutr.* 2012;54:136–60.
- 385 5. Al-Bawardy B, Codipilly DC, Rubio-Tapia A, Bruining DH, Hansel SL, Murray JA. Celiac disease: a clinical review. *Abdom Radiol N Y.* 2017;42:351–60.
6. Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PHR, et al. The Oslo definitions for coeliac disease and related terms. *Gut.* 2013;62:43–52.
- 390 7. Popp A, Kivelä L, Fuchs V, Kurppa K. Diagnosing Celiac Disease: Towards Wide-Scale Screening and Serology-Based Criteria? *Gastroenterol Res Pract.* 2019;2019:2916024.
8. Stein AC, Liao C, Paski S, Polonsky T, Semrad CE, Kupfer SS. Obesity and Cardiovascular Risk in Adults With Celiac Disease. *J Clin Gastroenterol.* 2016;50:545–50.
9. Capriati T, Francavilla R, Ferretti F, Castellaneta S, Ancinelli M, Diamanti A. The overweight: a rare presentation of celiac disease. *Eur J Clin Nutr.* 2016;70:282–4.
- 395 10. Aminian A, Andalib A, Ver MR, Corcelles R, Schauer PR, Brethauer SA. Outcomes of Bariatric Surgery in Patients with Inflammatory Bowel Disease. *Obes Surg.* 2016;26:1186–90.
11. Deveney CW. Bariatric surgery in severely obese patients with inflammatory bowel disease: a systematic review. *Surg Obes Relat Dis Off J Am Soc Bariatr Surg.* 2017;13:659–60.
- 400 12. Dubé C, Rostom A, Sy R, Cranney A, Saloojee N, Garritty C, et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. *Gastroenterology.* 2005;128:S57-67.
- 405 13. Andrén Aronsson C, Lee H-S, Hård Af Segerstad EM, Uusitalo U, Yang J, Koletzko S, et al. Association of Gluten Intake During the First 5 Years of Life With Incidence of Celiac Disease Autoimmunity and Celiac Disease Among Children at Increased Risk. *JAMA.* 2019;322:514–23.
14. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA, American College of Gastroenterology. ACG clinical guidelines: diagnosis and management of celiac disease. *Am J Gastroenterol.* 2013;108:656–76; quiz 677.
- 410 15. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96:1911–30.
- 415 16. Zanchetta MB, Longobardi V, Bai JC. Bone and Celiac Disease. *Curr Osteoporos Rep.* 2016;14:43–8.
17. Caruso R, Pallone F, Stasi E, Romeo S, Monteleone G. Appropriate nutrient supplementation in celiac disease. *Ann Med.* 2013;45:522–31.
18. Dahele A, Ghosh S. Vitamin B12 deficiency in untreated celiac disease. *Am J Gastroenterol.* 2001;96:745–50.
- 420 19. Kempainen TA, Kosma VM, Janatuinen EK, Julkunen RJ, Pikkarainen PH, Uusitupa MI. Nutritional status of newly diagnosed celiac disease patients before and after the institution of a celiac disease diet--association with the grade of mucosal villous atrophy. *Am*

- J Clin Nutr. 1998;67:482–7.
- 425 20. Valdimarsson T, Toss G, Löfman O, Ström M. Three years' follow-up of bone density in adult coeliac disease: significance of secondary hyperparathyroidism. *Scand J Gastroenterol.* 2000;35:274–80.
21. Sategna-Guidetti C, Grosso SB, Grosso S, Mengozzi G, Aimo G, Zaccaria T, et al. The effects of 1-year gluten withdrawal on bone mass, bone metabolism and nutritional status in
430 newly-diagnosed adult coeliac disease patients. *Aliment Pharmacol Ther.* 2000;14:35–43.
22. Wierdsma NJ, van Bokhorst-de van der Schueren MAE, Berkenpas M, Mulder CJJ, van Bodegraven AA. Vitamin and mineral deficiencies are highly prevalent in newly diagnosed celiac disease patients. *Nutrients.* 2013;5:3975–92.
23. Deora V, Aylward N, Sokoro A, El-Matary W. Serum Vitamins and Minerals at
435 Diagnosis and Follow-up in Children With Celiac Disease. *J Pediatr Gastroenterol Nutr.* 2017;65:185–9.
24. Matysiak-Budnik T, Fabiani B, Hennequin C, Thieblemont C, Malamut G, Cadiot G, et al. Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD,
440 SFED, SFRO, SFH). *Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver.* 2018;50:124–31.
25. Cellier C, Delabesse E, Helmer C, Patey N, Matuchansky C, Jabri B, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. *Lancet Lond Engl.* 2000;356:203–8.
- 445 26. Ilus T, Kaukinen K, Virta LJ, Pukkala E, Collin P. Incidence of malignancies in diagnosed celiac patients: a population-based estimate. *Am J Gastroenterol.* 2014;109:1471–7.
27. Howdle PD, Jalal PK, Holmes GKT, Houlston RS. Primary small-bowel malignancy in the UK and its association with coeliac disease. *QJM Mon J Assoc Physicians.* 2003;96:345–53.
- 450 28. Sharma P, McCarty TR, Lange A, Ngu JN, Njei B. Impact of bariatric surgery on outcomes of patients with celiac disease: a nationwide inpatient sample analysis, 2004–2014. *Ann Gastroenterol.* 2019;32:73–80.
29. Dickey W, Kearney N. Overweight in celiac disease: prevalence, clinical characteristics, and effect of a gluten-free diet. *Am J Gastroenterol.* 2006;101:2356–9.
- 455 30. Singh I, Agnihotri A, Sharma A, Verma AK, Das P, Thakur B, et al. Patients with celiac disease may have normal weight or may even be overweight. *Indian J Gastroenterol Off J Indian Soc Gastroenterol.* 2016;35:20–4.
31. Cheng J, Brar PS, Lee AR, Green PHR. Body mass index in celiac disease: beneficial effect of a gluten-free diet. *J Clin Gastroenterol.* 2010;44:267–71.
- 460 32. Ukkola A, Mäki M, Kurppa K, Collin P, Huhtala H, Kekkonen L, et al. Changes in body mass index on a gluten-free diet in coeliac disease: a nationwide study. *Eur J Intern Med.* 2012;23:384–8.
33. Tucker E, Rostami K, Prabhakaran S, Al Dulaimi D. Patients with coeliac disease are increasingly overweight or obese on presentation. *J Gastrointest Liver Dis JGLD.*
465 2012;21:11–5.
34. Kabbani TA, Goldberg A, Kelly CP, Pallav K, Tariq S, Peer A, et al. Body mass index and the risk of obesity in coeliac disease treated with the gluten-free diet. *Aliment Pharmacol Ther.* 2012;35:723–9.
35. Reilly NR, Aguilar K, Hassid BG, Cheng J, Defelice AR, Kazlow P, et al. Celiac disease
470 in normal-weight and overweight children: clinical features and growth outcomes following a gluten-free diet. *J Pediatr Gastroenterol Nutr.* 2011;53:528–31.
36. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. *JAMA.* 2012;307:56–65.

- 475 37. Kizy S, Jahansouz C, Downey MC, Hevelone N, Ikramuddin S, Leslie D. National Trends
in Bariatric Surgery 2012-2015: Demographics, Procedure Selection, Readmissions, and Cost.
Obes Surg. 2017;27:2933–9.
- 480 38. Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, et al. Clinical
practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of
patients undergoing bariatric procedures - 2019 update: cosponsored by American
Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity
Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association,
and American Society of Anesthesiologists. *Surg Obes Relat Dis Off J Am Soc Bariatr Surg.*
2020;16:175–247.
- 485 39. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrenbach K, et al. Bariatric
surgery: a systematic review and meta-analysis. *JAMA.* 2004;292:1724–37.
40. Via MA, Mechanick JI. Nutritional and Micronutrient Care of Bariatric Surgery Patients:
Current Evidence Update. *Curr Obes Rep.* 2017;6:286–96.
- 490 41. Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for
Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical
Weight Loss Patient 2016 Update: Micronutrients. *Surg Obes Relat Dis Off J Am Soc Bariatr
Surg.* 2017;13:727–41.
- 495 42. Busetto L, Dicker D, Azran C, Batterham RL, Farpour-Lambert N, Fried M, et al.
Practical Recommendations of the Obesity Management Task Force of the European
Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management.
Obes Facts. 2017;10:597–632.
- 500 43. Freeman LM, Strong AT, Sharma G, Panchai S, Rodriguez JH, Kirby DF, et al.
Implications of Celiac Disease Among Patients Undergoing Gastric Bypass. *Obes Surg.*
2018;28:1546–52.
44. de'Angelis N, Carra MC, Vincenzi F. Gluten-free diet in obese patients with celiac
disease: an enemy of the bariatric surgeon? *Obes Surg.* 2012;22:995–6.
- 505 45. Malli CP, Sioulas AD, Emmanouil T, Dimitriadis GD, Triantafyllou K. Endoscopy after
bariatric surgery. *Ann Gastroenterol.* 2016;29:249–57.
46. Pané A, Orois A, Careaga M, Saco A, Ortega E, Vidal J, et al. Clinical onset of celiac
disease after duodenal switch: a case report. *Eur J Clin Nutr.* 2016;70:1078–9.
- 510 47. Maple JT, Pearson RK, Murray JA, Kelly DG, Lara LF, Fan AC. Silent celiac disease
activated by pancreaticoduodenectomy. *Dig Dis Sci.* 2007;52:2140–4.
48. Cuenca-Abente F, Nachman F, Bai JC. Diagnosis of celiac disease during pre-operative
work-up for bariatric surgery. *Acta Gastroenterol Latinoam.* 2012;42:321–4.
49. Barone M, Della Valle N, Rosania R, Facciorusso A, Trotta A, Cantatore FP, et al. A
comparison of the nutritional status between adult celiac patients on a long-term, strictly
gluten-free diet and healthy subjects. *Eur J Clin Nutr.* 2016;70:23–7.
50. Tortora R, Capone P, De Stefano G, Imperatore N, Gerbino N, Donetto S, et al. Metabolic
syndrome in patients with coeliac disease on a gluten-free diet. *Aliment Pharmacol Ther.*
2015;41:352–9.

515

Figure legends

Figure 1. Clinical manifestations of celiac disease (gastrointestinal in green) and possible impact of bariatric surgery

520

Table 1: Frequency and consequences of nutrient deficiencies in celiac disease

Absorption site	Nutrient	Frequency of nutrient deficiencies symptomatic	Main clinical signs of nutrient deficiency reported
Duodenum-jejunum	Proteins Carbohydrates Lipids	60–100%	Weight loss, amyotrophy, hypoalbuminemia, undernutrition
	Iron	40–60%	Microcytic anemia, hair loss
	Calcium	25–45%	Osteopenia, tetany, secondary hyperparathyroidism
	Magnesium	15%	Muscular cramps, tetany
	Vitamin A	15%	Night vision disorders, infection
	Vitamin B1	-	Peripheral neuropathy, Wernicke encephalopathy
	Vitamin B6	-	Normocytic anemia
	Vitamin B9	10–90%	Macrocytic anemia
	Vitamin D	10–60%	Osteopenia, tetany, secondary hyperparathyroidism, bone loss, osteomalacia
	Vitamin K	30%	Bruising, coagulopathy
	Zinc	30–50%	Anorexia, hypoguesia, delayed growth, impaired wound healing
Ileum	Vitamin B12	15–40%	Macrocytic anemia, peripheral neuropathy

Table 2. Prevalence of underweight, normal weight, overweight and obesity in CD as assessed with BMI

525

Study	Number of patients	Underweight	Normal	Overweight	Obese
Am J Gastroenterol 2006 [38]	371	5%	57%	39%	13%
Indian J gastroenterol 2016 [30]	210	36%	54.8%	6.2%	2.9%
J Clin Gastroenterol 2010 [31]	369	17.3%	60.7%	15.2%	6.8%
Eur J Intern Med 2012 [32]	698	4%	57%	28%	11%
J Gastrointestin Liver Dis 2012 [33]	187	3%	53%	31%	13%

530 Table 3. Changes in weight category before and after initiation of a gluten-free diet (reported as % of total cohort).

Study	n	Duration of GFD (months)	UW before GFD	NW before GFD	OW before GFD	Obese before GFD
Barone et al. [49]	39	24.3	Gained weight: 50% Lost weight: 0%	Gained weight: 0% Lost weight: 0%	Gained weight: 0% Lost weight: 11%	Gained weight: 0% Lost weight: 0%
Tortora et al. [50]	98	12	Gained weight: 60% Lost weight: 0%	Gained weight: 12% Lost weight: 0%	Gained weight: 0% Lost weight: 0%	Gained weight: 0% Lost weight: 0%
Kabbani et al. [34]	679	39.5	N=46 Gained weight*: 52% Lost weight**: 2%	N=416 Gained weight*: 21% Lost weight**: 5%	N=139 Gained weight*: 22% Lost weight**: 18%	N= 8 Gained weight*: 22% Lost weight**: 23%
Ukkola et al. [32]	698	12	N=28 Gained weight: 69% Lost weight: 0%	N=398 Gained weight: 38% Lost weight: 10%	N=195 Gained weight: 22% Lost weight: 18%	N=77 Gained weight: 16% Lost weight: 42%
Cheng et al. [31]	369	33.6	N=64 Gained weight: 66% Lost weight: 27%	N=224 Gained weight: 58% Lost weight: 37%	N=56 Gained weight: 40% Lost weight: 54%	N=25 Gained weight: 18% Lost weight: 47%
Dickey et al. [29]	188	24	N=27 Gained weight: 93% Lost weight: NA	N=94 Gained weight: 77% Lost weight: NA	N=67 Gained weight: 82% Lost weight: NA	NA

UW = Underweight (BMI < 18.5 kg/m²)

NW = Normal weight (BMI 18.6–24.9 kg/m²)

535 OW = Overweight (BMI 25–29.9 kg/m²)

NA = not available

* defined as a BMI increase of 2 points or more; ** defined as a BMI of 2 points or more